The product pipeline for Non-Hodgkin Lymphoma (NHL) exhibits a lower degree of innovation than both the industry and oncology average. Just 28% of all pipeline products, or 33% of the pipeline for which there is a disclosed molecular target, are categorized as first-in-class. In comparison, industry, breast cancer and lung cancer exhibit innovation rates of 43%, 57% and 59%, respectively. While NHL, collectively, is the sixth to tenth most common cancer dependent on territory, each individual subtype is classified as an orphan disease. With significant differences in each subtype’s genetic profile and current treatment, there is reduced scope for the development of a targeted therapy with cross-subtype activity. This does not present NHL drug development as an attractive investment in comparison to other indications in oncology, particularly since the survival durations across many NHL subtypes are relatively strong, and likely the reason for low first-in-class innovation levels.
GBI Research’s Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma report includes information on the current clinical and commercial landscape, and the composition of the NHL therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.
Key highlights from the report:
- There are 666 marketed products for NHL, 95% of which are small molecules
- The treatment of lymphoma is dominated by the use of combination cyclophosphamide based chemotherapy in combination with rituximab
- The variation in molecule type has shifted away from small molecules, whose dominance has decreased to 46% across the pipeline
- There is a significant shift away from cytotoxic agents, with the current pipeline dominated by cancer immunotherapies and signal transduction inhibitors
Despite the difficulty in achieving improved efficacy rates, the development of such treatments remains of key interest across NHL. Find out more!